
A/Prof David Elliott
A/Prof David Elliott
Details
Role
Group Leader / Principal Research Fellow
Research area
Stem cell biology
Group
Heart Disease
Contact
Available for student supervision
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Assoc. Prof. Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.
Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers,...
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Assoc. Prof. Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.
Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Top Publications
- Huurne, MT, Parker, BL, Liu, NQ, Qian, EL, Vivien, C, Karavendzas, K, Mills, RJ, Saville, JT, Abu-Bonsrah, D, Wise, AF, et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals. American Journal of Human Genetics 110(9) : 1600 -1605 2023 view publication
- Ottaviani, D, Huurne, MT, Elliott, DA, Bellin, M, Mummery, CL. Maturing differentiated human pluripotent stem cells in vitro: methods and challenges. Development 150(11) : 2023 view publication
- Rudraraju, R, Gartner, MJ, Neil, JA, Stout, ES, Chen, J, Needham, EJ, See, M, Mackenzie-Kludas, C, Lee, LYY, Wang, M, et al. Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment. Stem Cell Reports 18(6) : 1308 -1324 2023 view publication
- Voges, HK, Foster, SR, Reynolds, L, Parker, BL, Devilée, L, Quaife-Ryan, GA, Fortuna, PRJ, Mathieson, E, Fitzsimmons, R, Lor, M, et al. Vascular cells improve functionality of human cardiac organoids. Cell Reports 42(5) : 112322 2023 view publication
- Felmingham, B, Collier, L, Stenta, T, Halman, A, Sadedin, S, Moore, C, Elliott, D, Conyers, R. MARVEL-PIC: minimising adverse drug reactions and verifying economic legitimacy: pharmacogenomic implementation in children. Pathology 55: s6 2023 view publication
Page 1 of 21